KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Non-Current Deffered Revenue (2016 - 2022)

Inovio Pharmaceuticals (INO) has disclosed Non-Current Deffered Revenue for 13 consecutive years, with $56935.0 as the latest value for Q2 2022.

  • Quarterly Non-Current Deffered Revenue fell 20.69% to $56935.0 in Q2 2022 from the year-ago period, while the trailing twelve-month figure was $56935.0 through Jun 2022, down 20.69% year-over-year, with the annual reading at $64361.0 for FY2021, 18.75% down from the prior year.
  • Non-Current Deffered Revenue hit $56935.0 in Q2 2022 for Inovio Pharmaceuticals, down from $60648.0 in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $9.0 million in Q1 2018 to a low of $56935.0 in Q2 2022.
  • Historically, Non-Current Deffered Revenue has averaged $1.1 million across 5 years, with a median of $86641.0 in 2020.
  • Biggest five-year swings in Non-Current Deffered Revenue: soared 3841.8% in 2018 and later plummeted 98.57% in 2019.
  • Year by year, Non-Current Deffered Revenue stood at $150793.0 in 2018, then crashed by 32.64% to $101567.0 in 2019, then decreased by 22.01% to $79214.0 in 2020, then fell by 18.75% to $64361.0 in 2021, then dropped by 11.54% to $56935.0 in 2022.
  • Business Quant data shows Non-Current Deffered Revenue for INO at $56935.0 in Q2 2022, $60648.0 in Q1 2022, and $64361.0 in Q4 2021.